TY - JOUR
T1 - Atherogenic Dyslipidemia in Latin America
T2 - Prevalence, causes and treatment: Expert's position paper made by The Latin American Academy for the Study of Lipids (ALALIP) Endorsed by the Inter-American Society of Cardiology (IASC), the South American Society of Cardiology (SSC), the Pan-American College of Endothelium (PACE), and the International Atherosclerosis Society (IAS)
AU - Ponte-Negretti, Carlos I.
AU - Isea-Perez, Jesus E.
AU - Lorenzatti, Alberto J.
AU - Lopez-Jaramillo, Patricio
AU - Wyss-Q, Fernando Stuardo
AU - Pintó, Xavier
AU - Lanas, Fernando
AU - Medina, Josefina
AU - Machado-H, Livia T.
AU - Acevedo, Monica
AU - Varleta, Paola
AU - Bryce, Alfonso
AU - Carrera, Carlos
AU - Peñaherrera, Carlos Ernesto
AU - Gómez-M, José Ramón
AU - Lozada, Alfredo
AU - Merchan-V, Alonso
AU - Piskorz, Daniel
AU - Morales, Enrique
AU - Paniagua, Maria
AU - Medina-Palomin, Félix
AU - Villar-M, Raul Alejandro
AU - Cobos, Leonardo
AU - Gómez-Alvares, Enrique
AU - Alonso, Rodrigo
AU - Colan, Juan
AU - Chirinos, Julio
AU - Lara, Jofre
AU - Ullauri, Vladimir
AU - Arocha, Ildefonso
N1 - Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2017/9/15
Y1 - 2017/9/15
N2 - This is an executive summary made by a group of experts named Latin American Academy for the study of Lipids (ALALIP). In the current clinical guidelines, atherogenic dyslipidemia (AD) is a poorly recognized entity. Due to the frequent lipid alterations associated with AD in Latin America (LA), we organized a group of experts named (ALALIP) to generate a document in order to analyze their prevalence and to offer practical recommendations. Methodology: using the Delphi methodology, we conducted a comprehensive literature review with emphasis on those publications related to LA. Subsequently, we developed key questions for discussion. As a convention, those recommendations that had a 100% of acceptance were considered unanimous, those with >80% were consensual, and those with <80% were in disagreement. Results: a systematic analysis of national health surveys and regional cohort studies showed a consistently high prevalence of the lipid abnormalities that define AD: low levels of high-density lipoprotein cholesterol (HDL-C) range from 34.1% to 53.3% and elevated triglycerides (TG) range from 25.5% to 31.2%. These abnormalities could be related to high consumption of food with a high caloric density, cholesterol and trans fats, a sedentary lifestyle and perhaps epigenetic changes Conclusions lipid abnormalities that define AD have a high prevalence in LA. The interaction between an unfavorable lifestyle, inheritance and epigenetic changes is probably their cause. It is important to design a global study of risk factors in LA to know its true prevalence in the region, its consequences and to derive from its treatment strategies.
AB - This is an executive summary made by a group of experts named Latin American Academy for the study of Lipids (ALALIP). In the current clinical guidelines, atherogenic dyslipidemia (AD) is a poorly recognized entity. Due to the frequent lipid alterations associated with AD in Latin America (LA), we organized a group of experts named (ALALIP) to generate a document in order to analyze their prevalence and to offer practical recommendations. Methodology: using the Delphi methodology, we conducted a comprehensive literature review with emphasis on those publications related to LA. Subsequently, we developed key questions for discussion. As a convention, those recommendations that had a 100% of acceptance were considered unanimous, those with >80% were consensual, and those with <80% were in disagreement. Results: a systematic analysis of national health surveys and regional cohort studies showed a consistently high prevalence of the lipid abnormalities that define AD: low levels of high-density lipoprotein cholesterol (HDL-C) range from 34.1% to 53.3% and elevated triglycerides (TG) range from 25.5% to 31.2%. These abnormalities could be related to high consumption of food with a high caloric density, cholesterol and trans fats, a sedentary lifestyle and perhaps epigenetic changes Conclusions lipid abnormalities that define AD have a high prevalence in LA. The interaction between an unfavorable lifestyle, inheritance and epigenetic changes is probably their cause. It is important to design a global study of risk factors in LA to know its true prevalence in the region, its consequences and to derive from its treatment strategies.
UR - http://www.scopus.com/inward/record.url?scp=85019860912&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2017.05.059
DO - 10.1016/j.ijcard.2017.05.059
M3 - Artículo Científico
C2 - 28552520
AN - SCOPUS:85019860912
SN - 0167-5273
VL - 243
SP - 516
EP - 522
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -